Medicine
Anascorp 7 mg/mL powder for injection
Anascorp 7 mg/mL powder for injection is a prescription medicine containing Centruroides fab2 antivenin (equine) for intravenous use, marketed by Rare Disease Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
DO NOT FREEZE. Store at room temperature (up to 25 ºC (77 ºF)). Brief…
Key facts
- Active ingredient (INN)
- Centruroides fab2 antivenin (equine)
- Brand
- Anascorp
- Strength
- 7 mg/mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Rare Disease Therapeutics
- Manufacturer
- Rare Disease Therapeutics
- Origin register
- US FDA, United States
- Storage
- DO NOT FREEZE. Store at room temperature (up to 25 ºC (77 ºF)). Brief temperature excursions are permitted up to 40 ºC (104ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.12Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 August 2011
- Identifiers
- RxCUI 1119989, 1119993DailyMed set ID 5cb65048-a30c-48e5-8bc8-897983d08068NDC 66621-0150Application BLA125335
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 10 mL in 1 vial | 66621-0150-2 | Rare Disease Therapeutics | 3 August 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Centruroides fab2 antivenin (equine) is an antivenin indicated for the treatment of clinical signs of scorpion envenomation. It is available as powder for injection for intravenous use. MedsAcross supplies Centruroides fab2 antivenin (equine) for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Centruroides fab2 antivenin (equine)For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ANASCORP prescribing information (Rare Disease Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Anascorp 7 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.